| scholarly article | Q13442814 |
| P2093 | author name string | Marjorie Perloff | |
| Vernon E. Steele | |||
| P2860 | cites work | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies | Q37337123 |
| Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. | Q37496366 | ||
| Phase 0 clinical trials: an answer to drug development stagnation? | Q46052036 | ||
| Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing | Q47935355 | ||
| Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 | Q34701702 | ||
| Phase 0 trials: expediting the development of chemoprevention agents | Q34802510 | ||
| Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies | Q36466906 | ||
| Designing phase 0 cancer clinical trials | Q36732115 | ||
| Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials | Q37160786 | ||
| Phase 0 trials: an industry perspective | Q37193278 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug design | Q2991682 |
| P304 | page(s) | 379-383 | |
| P577 | publication date | 2013-03-06 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | Early-phase development of cancer prevention agents: challenges and opportunities | |
| Early-Phase Development of Cancer Prevention Agents: Challenges and Opportunities | |||
| P478 | volume | 6 |
Search more.